Ritonavir overdosage: Difference between revisions
(Created page with "__NOTOC__ {{Ritonavir }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVIR (RITONAVIR) CAPSULE [ABBVIE INC.] | ur...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Overdosage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVIR (RITONAVIR) CAPSULE [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13b059c6-0c6c-49a5-b985-a4b05caf9ac9 | publisher = | date = | accessdate = }}</ref> | ===Acute Overdosage - Human Overdose Experience=== | ||
Human experience of acute overdose with NORVIR is limited. One patient in clinical trials took NORVIR 1500 mg per day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of [[renal failure]] with[[ eosinophilia]] has been reported with ritonavir overdose. | |||
The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice. | |||
===Management of Overdosage=== | |||
Treatment of overdose with NORVIR consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with NORVIR. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since ritonavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. A Certified Poison Control Center should be consulted for up-to-date information on the management of overdose with NORVIR.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVIR (RITONAVIR) CAPSULE [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13b059c6-0c6c-49a5-b985-a4b05caf9ac9 | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 17:52, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overdosage
Acute Overdosage - Human Overdose Experience
Human experience of acute overdose with NORVIR is limited. One patient in clinical trials took NORVIR 1500 mg per day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure witheosinophilia has been reported with ritonavir overdose.
The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
Management of Overdosage
Treatment of overdose with NORVIR consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with NORVIR. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since ritonavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. A Certified Poison Control Center should be consulted for up-to-date information on the management of overdose with NORVIR.[1]
References
Adapted from the FDA Package Insert.